Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02760069 · ClinicalTrials.gov registry record · Phase 4

Isopropyl Alcohol vs Ondansetron for Nausea in the Emergency Department

A Phase 4 study of Nausea, sponsored by Brooke Army Medical Center.

Completed
Registry status
Phase 4
Development phase
122
Enrollment target
1
Study location

NCT02760069 is a Phase 4 study of Nausea that has completed, run by Brooke Army Medical Center. The registered enrollment target is 122 participants, below the 237-participant average among 17 other Nausea trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02760069, a Phase 4 study of Nausea, has completed, sponsored by Brooke Army Medical Center.

COMPLETED
Registry status
Phase 4
Development phase
122 participants
Enrollment target
1
Study location

Study Summary

This study will compare the efficacy of isopropyl alcohol and conventional anti-emetics with three study arms: (1) inhaled isopropyl alcohol plus oral ondansetron; (2) inhaled isopropyl alcohol plus oral placebo; (3) inhaled placebo plus oral ondansetron.

Conditions Studied

Interventions

  • DRUG Inhaled isopropyl alcohol
  • DRUG Oral ondansetron
  • DRUG Inhaled normal saline
  • DRUG Oral placebo

Study Locations (1)

Texas

  • San Antonio Military Medical Center - San Antonio

Trial Details

FieldValue
Enrollment Target 122 participants
Start Date 2016-01
Est. Completion 2017-11
Phase Phase 4

Sponsor

Brooke Army Medical Center

54 total trials

What the Registry Record Tells You About NCT02760069

The ClinicalTrials.gov registry entry for NCT02760069 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 237-participant average among 17 other Nausea trials with a reported enrollment target (49% lower). The listed sponsor is Brooke Army Medical Center, which has 54 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Nausea appearing as the primary indexed condition, and to 4 interventions - of which Inhaled isopropyl alcohol is the first listed.

NCT02760069 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02760069 about?

NCT02760069 is a clinical study titled "Isopropyl Alcohol vs Ondansetron for Nausea in the Emergency Department". This study will compare the efficacy of isopropyl alcohol and conventional anti-emetics with three study arms: (1) inhaled isopropyl alcohol plus oral ondansetron; (2) inhaled isopropyl alcohol plus oral placebo; (3) inhaled placebo plus oral ondansetron.

What is the current status of trial NCT02760069?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 122 participants. The study started on 2016-01. Estimated completion is 2017-11.

What conditions does trial NCT02760069 study?

This clinical trial studies the following conditions: Nausea.

What interventions are being tested in trial NCT02760069?

The interventions under investigation include: Inhaled isopropyl alcohol (DRUG), Oral ondansetron (DRUG), Inhaled normal saline (DRUG), Oral placebo (DRUG).

Who is sponsoring clinical trial NCT02760069?

This trial is sponsored by Brooke Army Medical Center, which has 54 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02760069 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Nausea

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.